Abstract
If stably expressed in human embryonic kidney (HEK)293 cells, the human Mel1a-melatonin receptor activates Gi-dependent, pertussis toxin-sensitive signaling pathways, i.e., inhibition of adenylyl cyclase and stimulation of phospholipase Cβ; the latter on condition that Gq is coactivated. The antagonist luzindole blocks the effects of melatonin and acts as an inverse agonist at the Mel1a receptor in both intact cells and isolated membranes. This suggests that the Mel1areceptor is endowed with constitutive activity, a finding confirmed on reconstitution of the Mel1a receptor with Gi. Because the receptor density is in the physiological range, constitutive activity is not an artifact arising from overexpression of the receptor. In addition, the following findings indicate that the Mel1a receptor forms a very tight complex with Gi which can be observed both in the presence and absence of an agonist. 1) In intact cells and in membranes, high-affinity agonist binding is resistant to the destabilizing effect of guanine nucleotides. 2) The ability to bind an agonist with high affinity is preserved even after exposure of the cells to pertussis toxin, because a fraction of Gi is inaccessible to the toxin in cells expressing Mel1a receptors (but not the A1-adenosine receptor, another Gi-coupled receptor). 3) An antiserum directed against the Mel1areceptor coprecipitates Gi even in the absence of an agonist. We therefore conclude that the Mel1a receptor is tightly precoupled and that its constitutive activity may play a role in pacing the biological clock, an action known to involve the melatonin receptors in the suprachiasmatic nucleus.
Footnotes
- Received April 28, 1999.
- Accepted August 11, 1999.
-
Send reprint requests to: Dr. Christian Nanoff, Institute of Pharmacology, Vienna University, Wahringer Str. 13A, A-1090 Vienna, Austria. E-mail: christian.nanoff{at}univie.ac.at
-
This work was supported by grants from the Austrian Science Foundation (FWF) to C.N. (P-12125) and to M.F. (P-12079), by a grant from the Institut de Recherches Internationales de Servier, and by the European Union-sponsored concerted action European Network for Biological Signal Transduction.
- The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|